Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin

CONCLUSION: Baseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8+ cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.PMID:37733188 | DOI:10.1007/s10549-023-07086-9
Source: Cell Research - Category: Cytology Authors: Source Type: research